Lercanidipine + Enalapril
Asset
Combines calcium channel blockade and ACE inhibition to relax blood vessels and lower blood pressure.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Essential hypertension
Phase 2, Completed, NCT01093807, clinicaltrials.gov, Nov 1, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors12
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.